고려제약

014570KOSDAQ의약품 제조업

60.5 / 100

Reference Date: 2026-04-13

Financial Score28.0 / 40

News Sentiment12.5 / 25

Momentum10.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Slightly up 2.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Korea Pharmaceutical Co., Ltd. is a leading South Korean manufacturer of over-the-counter and specialty pharmaceuticals, renowned for its cold remedy 'Haben' and treatments for CNS diseases such as epilepsy and Parkinson's. The company's flagship products include CNS medications, which are sold through pharmacies, hospitals, and international exports, while also focusing on R&D for new drugs and health functional foods.

Number of Employees

238people

Average Salary

55.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

6.80Industry Average 14.808.0Point

Half of industry avg (excellent)

PBR

0.53Industry Average 1.045.5Point

Lower than industry avg (good)

ROE

8.08Industry Average 4.425.5Point

1.8x industry avg (good)

Debt Ratio

3.56Industry Average 11.988.0Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼12.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼36.8% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 2.0% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 0

Neutral
고려제약, 자사주 1709주 처분

Detailed Momentum

52-week position3.0Point

52w lower range (21%)

Current 4,025Won52-week high 4,97552-week low 3,765

1-month return4.0Point

1m +2.42% (slight rise)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral자기주식처분결과보고서2026-04-07
Neutral주요사항보고서(자기주식처분결정)2026-03-31
Neutral정기주주총회결과2026-03-20
Neutral기업가치제고계획(자율공시)2026-03-20